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Abstract: The reliability of the FASTPlaqueTB
(FPTB) test (Biotec Ltd.) for the rapid
diagnosis of pulmonary tuberculosis was
evaluated and its diagnostic performance was
compared with the Amplified Mycobacterium
Tuberculosis Direct (MTD) test (Gen-Probe)
by testing 80 sputum samples obtained from
77 patients.
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The results were compared to those of
mycobacterial culture, smear and clinical
course. After a chart review 14 culturenegative patients who had been on
antituberculosis therapy before the study
began were excluded from the final analysis.
Of the remaining 63 patients, 33 were
considered to have tuberculosis; 29 of them
were both smear and culture positive, for
whom FPTB gave a sensitivity of 27% and a
specificity of 97%. MTD exhibited a sensitivity

Introduction
Tuberculosis is the leading cause of death due to an
infectious agent. It affects one third of the world’s
population, and 95% of the disease burden was caused by
those born in developing countries (1). This situation is
likely to deteriorate in the future, with annual disease
rates expected to rise from 8.8 million in 1995 to 11.9
milllion per year in 2005 (2). According to the WHO
Global Tuberculosis Control Report 2000, Turkey is
among the countries with tuberculosis incidence rates of
25-49 per 100,000 (3), with an incidence rate of 30.3
per 100,000 (4).
Currently in Turkey, most laboratory diagnoses of
Mycobacterium tuberculosis are performed by acid-fast
staining and culture of decontaminated samples on solid
or liquid culture. Staining has low sensitivity, but is
considered a rapid and specific screening test of primary
samples. Culture on solid media has acceptable sensitivity
and specificity but is a very slow method, requiring up to
6 weeks to detect positive specimens. The use of

and a specificity of 91% and 93%,
respectively. In patients with a specimen
storage and antituberculosis therapy period of
≤ 7 days, FPTB sensitivity increased up to
53% (8/15).
These data suggest that even under optimal
conditions the sensitivity of FPTB is lower
than that of MTD, smear and culture tests. It
could be said, therefore, that FPTB for the
direct detection of M. tuberculosis complex in
respiratory specimens did not add an adjunct
value to smears and culture. Thus, we
conclude that the sensitivity of FPTB needs to
be improved in order to be used for a rapid
diagnosis of pulmonary tuberculosis.
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automated culture systems has considerably quickened
the diagnosis of M. tuberculosis, but even these
techniques require an average of 2 weeks to detect
positive specimens (5).
Recently, new products for the rapid diagnosis of
tuberculosis have become commercially available. One of
them is the Amplified Mycobacterium tuberculosis Direct
(MTD) test (Gen-Probe, San Diego, California, USA), a
system which uses the transcription mediated
amplification method to amplify M. tuberculosis complex
16S rRNA via DNA intermediates, followed by
chemiluminescence detection of the amplicon with an
acridinum ester-labelled DNA probe (6). The newly
developed FASTPlaqueTB (FPTB) test (Biotec Ltd.)
utilizes phage amplification technology (7) and clinical
studies have been carried out.
The purpose of the present study was to eveluate the
performance of the FPTB, in the diagnosis of pulmonary
tuberculosis.
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Materials and Methods
Study design: Clinical samples were collected from
the microbiology laboratories of the Regional
Tuberculosis Laboratory, ‹zmir, between December 2000
and December 2001. This laboratory serves around 8
million people living in western Turkey. The Regional
Tuberculosis Laboratory receives an average of 100
specimens per day for mycobacterial culture which are
obtained from patients of its 28 peripheral dispenseries.
Patient selection: Seventy-seven patients were
investigated. Patients included in the study were
separated into two groups: tuberculosis positive (Group
1), and tuberculosis negative (Group 2). For patients to
be considered to have tuberculosis (Group 1), they are
expected to meet one of the following criteria: (i) their
cultures are positive for M. tuberculosis; (ii) culturenegative patients’ acid-fast bacilli (AFB) smears are
positive and their clinical history and chest
roentgenograms sufficiently indicate tuberculosis; iii)
patients are diagnosed with either (i) or (ii) and are
receiving therapy for tuberculosis. Patients categorized as
Group 2 were excluded from being diagnosed as having
tuberculosis as (i) they were old tuberculosis patients
with negative AFB smears and cultures who were
clinically resolved; ii) they had nonspecific respiratory
symptoms and were culture negative and AFB smears
negative.
Clinical specimens, culture and microscopy: A total
of 80 sputum samples obtained from 77 patients were
investigated. Specimens were processed by NaOH
digestion and decontaminated by the N-acetyl-L-cysteine
NaOH method for culture (8). Each sample was divided
into two portions. While one portion was immediately
processed for culture, one half of the second portion was
stored at 4 °C for FPTB for 1-28 days and the other half
of the second portion was stored at –80 °C for MTD for
1-4 months. The processed sediments (0.5 ml) were
inoculated into Löwenstein-Jensen (L-J) slants.
Mycobacterial cultures were incubated at 37 °C for 8
weeks. L-J slants were examined weekly for positive
culture. The standard biochemical tests were performed
to identify M. tuberculosis isolates (8). Smears were
stained by the Zeihl-Neelsen method.
MTD: Gene-Probe RNA amplification was carried out
as described by the manufacturer. The samples were read
by a Leader 450 luminometer and a cut- off value of
500,000 RLU was used for positive specimens. Samples
488

that read between 30,000 and 500,000 RLU were
retested, and specimens above 30,000 RLU were
considered positive. In each run, negative and positive
controls were included.
FPTB: The mycobacteriophage assay was performed
as described by the manufacturer. A sample was
considered positive if the number of plaques on the plate
was greater than 20. When the number was less than 20,
the sample was considered negative. Samples were
evaluated only if 20-300 plaques were present on the
control plates including organisms, and if less than 10
plaques were present on the control plates without
organisms.
Statistical analysis: The sensitivity, specificity,
positive predictive value (PPV) and negative predictive
value (NPV) of MTD and FPTB were calculated in
comparison with culture results plus patients’ clinical
data. The differences between MTD and FPTB were
calculated by paired sample chi-square test. The effects of
the duration of antituberculosis treatment and storage
period to prior processing on the sensitivity of FPTB were
calculated by logistic regression. p < 0.05 indicated
significance. Data were evaluated by using SPSS 8.0.

Results
Seventy-seven patients (49 males and 28 females)
made up the patient population. While 33 of the 77
patients were considered to have tuberculosis (Group 1),
30 of the 77 patients were tuberculosis negative (Group
2). The remaining 14 patients were culture negative and
were receiving therapy (38 days to 236 days) for
tuberculosis and their former culture had been positive
for M. tuberculosis. Therefore they were excluded. Thirty
of the 33 tuberculosis patients were culture positive. The
remaning three patients were culture negative but smear
positive. In addition, their clinical history and chest
roentgenogram were sufficiently indicative of
tuberculosis. Ten of the 30 tuberculosis-negative patients
(Group 2), were old tuberculosis patients who were
culture negative and clinically resolved. Twenty patients
were culture and smear negative and had nonspecific
respiratory symptoms. For culture-positive specimens,
the average turnaround time was 4 weeks. The patient
groups included in the study are shown in Figure 1.
Susceptibility testing was performed for 26 of the 30
culture-positive patients. Nineteen of these 26 patients
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Figure 1.

77
(Total patients)

47
Group 1 (tuberculosis)
30

29

30
Group 2 (non-tuberculosis)
17

1

10

3
No therapy

14
Under therapy
(excluded)

3

7

0

AFB (+) AFB (-) AFB (+) AFB (-)

28 MTD (+)
9 FPTB (+)

Results of conventional and
diagnostic testing of patients
including in the study

2 MTD (+)

7

AFB (+) AFB (-)

0

20

10

0

AFB (+) AFB (-)

5 MTD (+) 5 MTD (+)
1 FPTB (+)

AFB (+)

1 MTD (+)

were infected with M. tuberculosis susceptible to all
primary drugs. Two patients had strains resistant to a
single drug (streptomycin one; rifampin one). Five
patients had strains resistant to more than one drug
(isoniazid, rifampin, streptomycin two; isoniazid,
ethambutole one).
After a reevaluation of the results, 33 patients were
considered to have tuberculosis, for which MTD and FPTB
gave a sensitivity of 91% and 27%, and a NPV of 90%
and 55%, respectively. Of the 30 culture-positive
patients, 28 were positive by MTD (sensitivity 93%) and
nine were positive by FPTB (sensitivity 27%). With the
two false positive MTD and one false positive FPTB
results, a specificity of 93% and 97%, and a PPV of 94%
and 90% were calculated, respectively. Table 1 shows the
comparison of FPTB with culture, smear and MTD.

20

AFB (-)

1MTD (+)
1FPTB (+)

Discussion
The increase in the incidence of tuberculosis has
stimulated the development of rapid direct detection
methods for the laboratory diagnosis of M. tuberculosis.
The Gen-Probe MTD is a standardized commercial
detection system and has already been used with a high
degree of sensitivity and specificity for the diagnosis of
pulmonary tuberculosis (9-12). Newly developed FPTB
utilizes phage amplification technology and clinical studies
have been carried out. The aims of this study were to
compare the diagnostic performance of FPTB with MTD
in pulmonary tuberculosis and to evaluate the effects of
the factors in routine application– including storage
period of the specimen prior to processing and duration
of the antituberculosis treatment– on the performance of
the FPTB.

Table1.

Comparison of FPTB with MTD, smear and culture for detection of tuberculosis infection (n = 63).

Method

Smear-pos.
culture-pos.
TB group (n = 29)

Smear-neg.
culture-pos.
TB group (n = 1)

Smear-pos.
culture-neg.
TB group (n = 3)

Smear-neg.
culture neg.
non-TB group (n = 30)

Sen
(%)

Spec
(%)

NPV
(%)

PPV
(%)

MTD

28

-

2

2

91

93

90

94

FPTB

9

-

-

1

27

97

55

90
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Fourteen culture-negative patients were receiving
antituberculosis therapy. Seven of the 14 patients were
smear positive, while the remaning seven were smear
negative. Therapy duration varied from 38 to 157 days
for smear-positive patients to 48 to 236 days for smearnegative patients. While 10 of these 14 patients were
positive by MTD, FPTB gave a positive result in only one
patient. MTD may be positive in culture-negative
specimens during therapy. The non-cultivable organism
shedding period can be extensive; the maximum time seen
may be 254 days but is usually much shorter. The exact
physical state of M. tuberculosis rRNA during the noncultivable organism shedding period is not known. A noncultivable organism shedding period detected by MTD
when the AFB smear results are also positive suggests
that intact organisms with a detectable rRNA sequence
are present. They do not reproduce in culture because
they are either totally nonviable or so damaged that they
can not grow on laboratory media (13,14). Therefore,
14 culture-negative patients receiving therapy were
excluded from the study due to uncertainty about the
presence of bacilli (viable or not) and were not further
evaluated.
Thirty-two samples obtained from 30 patients were
culture positive. All patients positive with FPTB were also
culture and AFB smear positive. Of the nine FPTB-positive
samples eight were stored prior to processing ≤ 7 days
and FPTB sensitivity was 50% (8/16) in specimens stored
≤ 7 days. The difference was statistically significant (R2 =
0.50, p < 0.05 y = 0.116-2.9 storage period). Five
culture-positive samples were obtained from four
patients who had been receiving antituberculosis therapy
> 7 days (15 to 58 days) and FPTB did not detect any of
them. Moreover, one of these patients’ (patient no. 1)
former sample (patient no. 6) obtained before starting
the antituberculosis therapy was positive by FPTB. In
patients with antituberculosis treatment and specimen
storage period ≤ 7 days, FPTB sensitivity increased to
53% (8/15) (Tables 2 and 3). These findings
demonstrate that the performance of FPTB is affected by
the duration of specimen storage and of the
antituberculosis treatment. It is argued that these factors
can decrease the viable bacilli in the specimens. In the
light of our findings, for a maximum performance by
FPTB, specimens must be obtained before starting
antituberculosis therapy and must be studied as soon as
possible. A preliminary clinical study carried out shows
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that under optimal conditions FPTB sensitivity in smearpositive samples is 81%, while in smear-negative samples
it is 25% (7). The sensitivity rates are in disagreement
with our findings. Although the number of patients we
studied was not very large, our sensitivity rate in optimal
conditions was still lower compared to the clinical study
above. MTD gave a sensitivity of 91%, and a specificity of
93%. The difference in sensitivity for the detection of M.
tuberculosis complex in sputum samples between MTD
and FPTB was statistically significant (x2 = 21 p < 0.05).
Microscopic examination of acid-fast staining smears
is a simple, rapid and inexpensive method; however, its
sensitivity is limited (5). Smear is a highly specific method
for populations such as ours where the prevalance of
nontuberculosis mycobacteria infections is low. In AFB
smear-positive patients with typical radiological and
clinical findings, antituberculosis therapy is begun after
the smear results are reported and generally no further
diagnostic efforts are necessary. Therefore, the rapid
diagnostic test is most beneficial in patient populations
where a reasonable proportion of the smear-positive
specimens contain nontuberculosis mycobacteria and in
smear-negative patients suspected of having tuberculosis.
However, FPTB can also give false positive results with
certain strains of some nontuberculosis mycobacteria.
Furthermore, the turnaround time of FPTB is around 48
h, which makes it slower than the smear. In addition, in
our study the sensitivity of FPTB was lower than that of
the smear.
Our results suggested that FPTB for direct detection
of M. tuberculosis complex in respiratory specimens did
not add any significant adjunct value to smears and
culture. In conclusion, it seems that FPTB needs to be
improved in terms of its sensitivity so that it becomes an
effective diagnostic tool for the rapid diagnosis of
pulmonary tuberculosis.
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Table 2.

Effects of the duration of antituberculosis treatment and storage period to prior processing on sensitivity of FPTB in culture-positive
specimens.

Patient no.

Storage period

Duration of the therapy

Susceptibility testing

MTD

FPTB

4

1 day

-

S

+

+

66

1 day

-

NA

+

+

11

1 day

-

S

+

-

13

1 day

-

R (SM)

+

-

67

2 days

4 days

S

+

+

33

2 days

-

S

+

+

63

3 days

-

S

+

-

14

4 days

3 days

S

+

+

15

4 days

2 days

S

-

-

29

5 days

-

R (INH, RIF, SM)

+

-

47

5 days

R (INH, RIF, SM)

+

-

12

7 days

-

S

+

+

26

7 days

-

R (RIF)

+

+

32

7 days

-

S

+

+

a

7 days

15 days

S

+

-

48

7 days

58 days

S

+

-

b

6

8 days

30 days

R (INH, RIF)

+

-

3

9 days

-

S

+

-

24

9 days

-

NA

+

-

18

13 days

-

S

+

-

19

13 days

41 days

S

+

-

20

15 days

38 days

NA

+

-

17

15 days

-

S

+

-

36

17 days

-

R (INH, ETB)

-

-

9

19 days

-

S

+

-

10

19 days

-

S

+

-

8

7

a

c

25 days

-

S

+

-

b

1

27 days

-

R (INH, RIF)

+

+

68

27 days

-

S

+

-

2

27 days

-

R (INH, RIF)

+

-

22

27 days

2 days

NA

+

-

31

28 days

-

S

+

-

a,b

Patients numbered 7 and 48, and patients numbered 1 and 6 are the same patients
Smear negative
S: Susceptible, R: Resistant, NA: Not applied
INH: Isoniazid, RIF: Rifampin, SM: Streptomycin, ETB: Ethambutole
c
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Table 3.

Under optimal conditions*, comparison of FPTB with smear and culture for detection of tuberculosis infection (n = 45).

Method

Smear-pos.
Culture pos.
TB group (n = 14)

Smear-pos.
Culture-neg.
TB group (n = 1)

Smear-neg.
culture neg.
non-TB group (n = 30)

Sen
(%)

Spec
(%)

NPV
(%)

PPV
(%)

FPTB

8

-

1

53

97

81

89

* Patients with duration of antituberculosis treatment and storage period to prior processing ≤ 7 days
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